Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients

British Journal of Clinical Pharmacology

Volumn 55, Issue 4, 2003, Pages 341-346

  Myou, Shigeharu ^a,c   Fujimura, Masaki ^a   Kamio, Yumie ^b   Hirose, Tatsuki ^a   Kita, Toshiyuki ^a   Tachibana, Hideki ^a   Ishiura, Yoshihisa ^a   Watanabe, Kazuyoshi ^a   Hashimoto, Takuma ^a   Nakao, Shinji ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^c NONE   (United States)

Author keywords

Aminophylline; Asthma; Bronchodilatation; Olprinone; Phosphodiesterase 3 inhibitors

Indexed keywords

AMINOPHYLLINE; LOPRINONE; PHOSPHODIESTERASE INHIBITOR; SODIUM CHLORIDE;

ADULT; ARTICLE; ASTHMA; BLOOD PRESSURE REGULATION; BRONCHODILATATION; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INFUSION; DRUG POTENTIATION; FEMALE; FORCED EXPIRATORY VOLUME; HEART RATE VARIABILITY; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADULT; AMINOPHYLLINE; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; DRUG COMBINATIONS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PYRIDONES; VITAL CAPACITY;

EID: 0038408570     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01760.x     Document Type: Article

References (15)

1. British Thoracic Society. Guidelines on the management of asthma. Thorax 1993; 48: S1-S24.
2. National Heart, Lung and Blood Institute. Guidelines for the diagnosis and management of asthma. National Asthma Education Program. Expert Panel Report. J Allergy Clin Immunol 1991; 88: 425-534.
3. National Asthma Project. International consensus report on diagnosis and treatment of asthma. Eur Respir J 1992; 5: 601-641.
4. Weinberger M. The pharmacology and therapeutic use of theophylline. J Allergy Clin Immunol 1984; 73: 525-540.
5. Galant SP, Lawrence M, Meltzer EO, Tomasko M, Baker KA, Kellerman DJ. Fluticasone propionate compared with theophylline for mild-to-moderate asthma. Ann Allergy Asthma Immunol 1996; 77: 112-118.
6. Polson JB, Krzanowski JJ, Goldman AL, Szentivanyi A. Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline. Clin Exp Pharmacol Physiol 1978; 5: 535-539.
7. Fujimura M, Kamio Y, Saito M, Hashimoto T, Matsuda T. Bronchodilator and bronchoprotective effects of cilostazol in humans in vivo. Am J Respir Crit Care Med 1995; 151: 222-225.
8. Fujimura M, Kamio Y, Myou S, Hashimoto T, Matsuda T. Effect of a phosphodiesterase 3 inhibitor, cilostazol, on bronchial hyperresponsiveness in elderly patients with asthma. Int Arch Allergy Immunol 1997; 114: 379-384.
9. Ogawa T, Ohhara H, Tsunoda H, Kuroki J, Shoji T. Cardiovascular effects of the new cardiotonic agent 1,2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a]pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate. First communication: studies on isolated guinea pig cardiac muscles. Arzneim-Forsch/Drug Res 1989; 39: 33-37.
10. Sugioka M, Ito M, Masuoka H et al. Identification and characterization of isoenzymes of cyclic nucleotide phosphodiesterase in human kidney and heart, and the effects of new cardiotonic agents on these isoenzymes. Naunyn Schmiedebergs Arch Pharmacol 1994; 350: 284-293.
11. Myou S, Fujimura M, Kamio Y et al. Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 817-820.
12. Foster RW, Rakshi K, Carpenter JR, Small RC. Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a methacholine challenge test. Br J Clin Pharmacol 1992; 34: 527-534.
13. American Thoracic Society. Standard for diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-244.
14. American Thoracic Society. Standardization of spirometry 1987 update. Am Rev Respir Dis 1987; 136: 1285-1298.
15. Atarashi H, Sasaki H, Ohsaka M et al. A phase I study of E-1020 - intravenous injection. Jpn J Clin Pharmacol Ther 1990; 21: 613-621.